Hypoglycemia secondary to sulfonylureas and clopidogrel have been independently described in the literature. However, there has been minimal investigation into the risk of clopidogrel-induced hypoglycemia in the setting of long-term or concomitant sulfonylurea use in patients with Type 2 diabetes mellitus. We present a case of a patient with diabetes well managed on glimepiride (second-generation sulfonylurea) for more than 10 years who presented with an episode of hypoglycemia shortly after initiation of clopidogrel for peripheral vascular disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314232 | PMC |
| http://dx.doi.org/10.7759/cureus.26306 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk of Hypoglycemia Associated with Concomitant Use of Insulin Secretagogues and ACE Inhibitors in Adults with Type 2 Diabetes: A Systematic Review.
Clin Pharmacol Ther
December 2024
Center for Real-World Effectiveness and Safety of Therapeutics, Center for Clinical Epidemiology and Biostatistics, and Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Insulin secretagogues and angiotensin-converting enzyme inhibitors (ACEIs) are commonly co-prescribed for patients with type 2 diabetes (T2D). Case reports suggesting that co-administration of insulin secretagogues with ACEIs is associated with an increased risk of serious hypoglycemia have led to warnings regarding a drug-drug interaction in widely used drug compendia. However, subsequent studies have had inconsistent results.
View Article and Find Full Text PDFThe Prevalent New-User Design to Study Drug-Drug Interactions: The Example of Sulfonylureas and Warfarin Interaction on the Risk of Severe Hypoglycemia.
Pharmacoepidemiol Drug Saf
October 2024
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
Article Synopsis
- The study aims to determine the effectiveness of the new-user design in pharmacoepidemiological research by examining the interaction between sulfonylureas and warfarin and its impact on severe hypoglycemia.
- Researchers analyzed data from patients in the UK's Clinical Practice Research Datalink between 1998 and 2020, matching patients using both medications with those using sulfonylureas alone.
- Results indicated no significant increase in the risk of severe hypoglycemia for patients taking both sulfonylureas and warfarin, suggesting that the new-user design is a viable method for studying drug-drug interactions.
TNFα and IL-8 vitreous concentrations variations with two antidiabetic therapies in patients with proliferative diabetic retinopathy: an observational study.
BMC Ophthalmol
September 2024
Centro de Investigación Biomédica, Fundación Hospital Nuestra Señora de la Luz I.A.P, Mexico City, Mexico.
Article Synopsis
- The study aimed to examine how antidiabetic therapies affect inflammatory cytokines in the vitreous humor of diabetic patients with retinopathy.
- Researchers analyzed samples from patients with type 2 diabetes receiving either insulin or a combination of metformin and glibenclamide, specifically measuring levels of several interleukins and TNFα.
- Results showed that insulin-treated patients had higher TNFα levels and lower interleukin-8 levels, while the opposite was true for those on metformin + glibenclamide; significant differences were noted, particularly in patients with retinal detachment.
Introduction: The aim of this work was to assess the safety and effectiveness of concomitant iGlarLixi and sodium-glucose co-transporter-2 inhibitors (SGLT-2i) use in adults with type 2 diabetes (T2D) who fasted during Ramadan.
Methods: Of the 420 eligible participants from the SoliRam study, 174 were using SGLT-2i in addition to iGlarLixi and 246 were not using SGLT-2i, referred to as SGLT-2i user and non-user, respectively. The primary endpoint was the proportion of participants experiencing ≥ 1 severe and/or symptomatic documented (< 70 mg/dl [< 3.
[Probable pharmacological interaction between sulfonylurea and beta-blocker in a patient with DM-II. A case report].
Farm Comunitarios
April 2024
Farmacéutico comunitario. Farmacia Zarzuelo, Benalmádena (Málaga). Farmacia España.
The study presents the case of a 47-year-old woman with type 2 diabetes (T2D), hypertension and anemia, treated with metformin, glyburide, metoprolol, and iron/folic acid. A drug interaction was identified between glyburide and metoprolol, causing symptoms of hypoglycemia in the afternoon. Evaluation using Horn's Drug Interaction Probability Scale (DIPS) suggested a probable interaction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!